For cancer patients, progress can mean more time, fewer side effects, and a better chance of recovery. For investors, the challenge is identifying companies that can turn scientific advances into effective treatments while building a sustainable business. A promising molecule can get Wall Street’s attention. Getting it through clinical trials, regulatory review, and into doctors’ hands requires more than a confident CEO and a presentation with excellent transitions.
The need remains enormous. The World Health Organization estimates that cancer caused nearly 10 million deaths worldwide in 2024. Many cancers can be cured when detected early and treated effectively, making prevention, diagnosis, and treatment essential parts of the oncology landscape. The medical need is clear long before an investment banker arrives to calculate the addressable market.
Understanding that landscape also means recognizing how much prevention matters. A WHO and International Agency for Research on Cancer analysis published in February 2026 identified tobacco, cancer-causing infections, and alcohol as the leading preventable causes globally, accounting for approximately 15%, 10%, and 3% of new cancer cases in 2022, respectively. Prevention rarely receives the stock-market standing ovation reserved for a successful drug trial, but its potential deserves considerably more attention. These population-level findings also do not make an individual diagnosis a matter of personal blame; many factors affecting cancer risk lie beyond a person’s control.
Cancer biology, meanwhile, refuses to simplify itself for social media. Although cancer cells often consume more glucose than normal cells, the National Cancer Institute says studies have not shown that eating sugar makes cancer worse or that eliminating it causes tumors to shrink or disappear. A high-sugar diet can contribute to excess weight gain, and obesity is associated with a greater risk of several cancers. Nutrition matters. A smoothie photographed in flattering natural light still needs evidence before it starts making medical claims.
The Next Oncology Breakthrough Needs More Than a Great Headline
The search for better cancer treatments involves many races against distinct diseases, each with its own biological obstacles. Declaring one company “closest to curing cancer” gives readers a convenient finish line. Unfortunately, cancer has yet to agree to the race rules.
A more useful approach is to examine which developers are delivering meaningful results in specific cancers, particularly where existing treatments leave patients with limited options. Investors should ask what a treatment actually does, whom it helps, and how convincingly the evidence supports it. “Potential breakthrough” is an invitation to investigate, rather than a reason to skip straight to the buy button.
AstraZeneca offers one example. As discussed in our coverage of AstraZeneca’s bid for FDA approval of a new lung cancer treatment, its ORPATHYS-Tagrisso combination targets a defined group of patients with advanced EGFR-mutated lung cancer involving MET overexpression or amplification after disease progression on EGFR-targeted therapy. The strategy addresses a particular resistance mechanism, illustrating how drugmakers can pursue better outcomes while extending established oncology franchises.
That specificity gives investors something useful to evaluate. A defined patient population, credible clinical results, and a clear treatment rationale provide a stronger foundation than another promise to “transform the future of medicine.” The future receives plenty of enthusiastic promises. Patients and regulators tend to request supporting documents.
Bristol Myers Squibb is pursuing progress through another platform. On October 12, 2026, the company reported that its experimental radiopharmaceutical RYZ101 delivered a statistically significant and clinically meaningful improvement in progression-free survival in the Phase 3 ACTION-1 trial. The study involved patients with certain gastroenteropancreatic neuroendocrine tumors whose disease had progressed after lutetium-177-based treatment. Detailed results were reserved for a future medical meeting, and follow-up for overall survival was continuing.
That distinction matters. Progression-free survival measures the time patients live without their disease worsening; it does not, by itself, establish a cure or an overall survival benefit. The result offers a concrete development to assess in a difficult treatment setting. Investors can appreciate the milestone without asking it to do the work of three additional milestones.
Big Pharma Is Writing Big Checks but Clinical Trials Still Mark the Papers
The financial commitments behind emerging oncology platforms can be substantial. On October 5, 2026, AstraZeneca completed a $2 billion equity investment in Summit Therapeutics, supporting the development of Summit’s ivonescimab in combination with antibody-drug conjugates. The companies’ collaboration includes evaluating ivonescimab with AstraZeneca’s experimental sonesitatug vedotin, alongside plans for broader combinations involving other cancer medicines.
Two billion dollars is a serious expression of interest. It is also a rather expensive way to say, “We think this deserves further study.” The investment provides financial backing and brings development resources to the opportunity. Clinical endpoints, however, remain impressively indifferent to the size of the check.
For investors, this is where the homework becomes more demanding. Trial design, safety, regulatory prospects, competition, funding needs, and valuation all shape whether scientific progress can produce lasting commercial value. A treatment may help patients and still face a difficult launch. A company may report encouraging results while its share price already assumes the sequel, the franchise, and the commemorative merchandise.
The commercial questions deserve the same scrutiny as the scientific ones. How many patients could qualify? How does the treatment compare with existing options? Can the company manufacture and supply it reliably? Will physicians adopt it, and will payers cover it? An impressive mechanism of action gets the discussion started. It does not automatically settle the reimbursement meeting.
The most compelling cancer stocks give investors something measurable to examine: demonstrated clinical benefits, a credible route toward approval, an established product franchise, or sufficient financial strength to reach the next meaningful milestone. Excitement can move a share price before lunch. Building a durable oncology business generally requires a longer calendar.
Against that backdrop, the following cancer stocks offer different ways to assess the evolving oncology opportunity, from established drugmakers expanding their franchises to developers pursuing their first commercial success. The aim is to find companies whose evidence, execution, and financial position can support the story—even after the presentation ends and someone turns the lights back on.
CHECK THIS OUT: 10 Best Biotech Stocks to Buy According to Billionaires
Our Methodology
To identify stocks with exposure to cancer care, we reviewed financial media coverage and internal research across pharmaceuticals, biotechnology, diagnostics, medical devices, life-sciences tools, healthcare distribution, and oncology services. Our selection reflects the breadth of companies supporting cancer detection, treatment, research, and patient care. We ranked the selected stocks in ascending order by the number of hedge funds holding stakes in each company as of Q2 2026, using hedge fund ownership as a measure of institutional interest rather than a guarantee of investment performance.
Guardant Health Inc. (NASDAQ:GH)
Number of Hedge Fund Holders — 80
Liquid Biopsy Gains a Broader Role in Cancer Treatment Decisions
Guardant Health, Inc. (NASDAQ: GH) is expanding its precision oncology business as blood-based testing becomes increasingly relevant to treatment selection and monitoring. On September 4, the FDA approved Guardant360 CDx as a companion diagnostic for camizestrant in a defined advanced breast cancer setting. The associated drug indication involves detecting an ESR1 mutation during treatment with an aromatase inhibitor and a CDK4/6 inhibitor. This development broadens the opportunity for molecular testing during ongoing care, rather than only at diagnosis. The distinction matters commercially because testing may become relevant as disease biology changes and physicians consider whether treatment should change with it.
The financial results show momentum across several parts of the business. Second-quarter revenue rose 44% to approximately $335 million, with oncology revenue increasing 38% to $219.1 million. Oncology testing volume grew 63% to roughly 104,000 tests. Screening added another source of expansion, generating $52.9 million in revenue as Shield test volume reached approximately 66,000, compared with about 16,000 a year earlier. Co-Chief Executive Officer Helmy Eltoukhy said growth was supported by “acceleration across every product.” Management raised its full-year revenue guidance to $1.34 billion–$1.36 billion, reflecting expected growth of 36%–38%.
For investors evaluating liquid biopsy stocks, the attraction is a business with several potential sources of demand: therapy selection, disease monitoring, screening, and services for pharmaceutical research. Each has different reimbursement and profitability considerations, making the quality of growth as important as the headline percentage. The companion diagnostic identifies patients eligible for a treatment; the drug’s clinical outcomes should not be credited to the test alone. Longer term, the investment case depends on converting clinical relevance into reimbursed volume while controlling laboratory, development, and commercial costs. A larger testing footprint creates opportunity, but sustainable margins must eventually do some of the talking.
Ranking rationale — Guardant Health, Inc. (NASDAQ: GH) ranks sixth with 80 hedge fund holders. Its breast cancer diagnostic expansion, oncology testing growth, and screening momentum support inclusion, while reimbursement, spending, and the conversion of revenue growth into durable profitability remain decisive.
YOU MUST READ THIS: 10 Promising Small-Cap Biotech Stocks to Watch and 10 Best Biotech Stocks Under $10 to Buy Now.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
